All In Biotech

Drug Trial Radar · NCT07005102

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 854 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

854

Planned (sponsor's estimate)

Start

Aug 3, 2025

Primary completion

Nov 2036

Study completion Nov 2036

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity "when telisotuzumab adizutecan is given in combination with a fixed dose of osimertinib (Osi)or standard of care (Osi plus platinum/pemetrexed chemotherapy). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. Osi is a drug approved for the treatment of NSCLC. This study will be divided into two stages, in the first stage participants will receive increasing doses of telisotuzumab adizutecan with Osi. Participants will then be randomized into 4 groups called treatment arms where 3 groups will receive 1 of 3 doses of telisotuzumab adizutecan from from the dose escalation phase with Osi, or standard of care (Osi plus chemotherapy). In the second stage participants will receive the optimal dose of telisotuzumab adizutecan, from the previous stage, with Osi, or SOC. Approximately 854 adult participants with 1L estimated glomerular filtration rate (EGFR) mut (mutated) not sufficient quantity (NSq) NSCLC will be enrolled in the study in 200 sites worldwide. In Stage 1, during dose escalation participants will receive increasing intravenous (IV) doses of telisotuzumab adizutecan with oral Osi tablets. participants will receive 1 of 3 doses of telisotuzumab adizutecan with Osi, or standard of care (Osi plus chemotherapy). In stage 2 participants will receive the optimal dose of IV telisotuzumab adizutecanin with oral Osi tablet, or SOC. The study will run for a duration of approximately 76 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Non-Squamous Non-Small Cell Lung Cancer
  • c-MET

Interventions

  • Standard of CareDrug

    Standard of Care

  • Telisotuzumab AdizutecanDrug

    Intravenous (IV)

  • Osimertinib (Osi)Drug

    Oral

  • CisplatinDrug

    IV

  • CarboplatinDrug

    IV

  • PemetrexedDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Time frame: Up to Approximately 76 Months
  2. Stage 2: Progression-free survival (PFS) based on BICR assessment per RECIST version 1.1.Time frame: Up to Approximately 76 Months
  3. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 76 Months

Locations

65 sites in 13 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers - Chandler /ID# 275443

    Chandler, Arizona · Recruiting

  • City of Hope National Medical Center /ID# 282241

    Duarte, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 284734

    Irvine, California · Recruiting

  • USC Norris Comprehensive Cancer Center /ID# 275343

    Los Angeles, California · Recruiting

  • Usc Norris Oncology/Hematology Treatment Center /ID# 278673

    Newport Beach, California · Recruiting

  • UCLA - Santa Monica /ID# 276816

    Santa Monica, California · Recruiting

  • City Of Hope - Upland /ID# 284650

    Upland, California · Recruiting

  • University Colorado Cancer Center /ID# 275382

    Aurora, Colorado · Recruiting

  • Mid Florida Hematology And Oncology Center /ID# 275278

    Orange City, Florida · Recruiting

  • Kaiser Permanente Moanalua Medical Center /ID# 275942

    Honolulu, Hawaii · Recruiting

  • The Iowa Clinic /ID# 276020

    West Des Moines, Iowa · Completed

  • Nho - Revive Research Institute /ID# 276115

    Lincoln, Nebraska · Recruiting

  • Renown Regional Medical Center /ID# 276049

    Reno, Nevada · Recruiting

  • Texas Oncology - South Austin /ID# 276033

    Austin, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center /ID# 275107

    Houston, Texas · Recruiting

  • Texas Oncology - Palestine Cancer Center /ID# 276034

    Palestine, Texas · Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 275071

    Fairfax, Virginia · Recruiting

  • University of Washington Medical Center /ID# 275866

    Seattle, Washington · Recruiting

  • Liverpool Hospital /ID# 276304

    Liverpool, New South Wales, Australia · Recruiting

  • The Queen Elizabeth Hospital /ID# 275719

    Woodville South, South Australia, Australia · Recruiting

  • Austin Health /ID# 275505

    Heidelberg, Victoria, Australia · Recruiting

  • St John of God Murdoch Hospital /ID# 275700

    Murdoch, Western Australia, Australia · Recruiting

  • CHU de Liege /ID# 277971

    Liège, Belgium · Recruiting

  • Jessa Ziekenhuis - Campus Virga Jesse /ID# 275585

    Hasselt, Limburg, Belgium · Recruiting

  • Universitair Ziekenhuis Leuven /ID# 275586

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • AZ-Delta. /ID# 275753

    Roeselare, West-Vlaanderen, Belgium · Recruiting

  • The Ottawa Hospital - General Campus /ID# 275611

    Ottawa, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre /ID# 274845

    Toronto, Ontario, Canada · Active not recruiting

  • Cancer Hospital - Chinese Academy of Medical Sciences /ID# 275631

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Province Cancer Hospital /ID# 274913

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital Of Guangzhou Medical University /ID# 274914

    Guangzhou, Guangdong, China · Recruiting

  • Union Hospital Tongji Medical College /ID# 278711

    Wuhan, Hubei, China · Recruiting

  • The First affiliated hospital of Nanchang University /ID# 275257

    Nanchang, Jiangxi, China · Recruiting

  • Shanghai Chest Hospital /ID# 275273

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University /ID# 274946

    Chengdu, Sichuan, China · Recruiting

  • Rambam Health Care Campus- Haifa /ID# 274542

    Haifa, Israel · Recruiting

  • Rabin Medical Center. /ID# 274540

    Petah Tikva, Central District, Israel · Recruiting

  • The Chaim Sheba Medical Center /ID# 274541

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 277808

    Perugia, Italy · Recruiting

  • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 280103

    Roma, Italy · Recruiting

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.